Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies
2017-000302-37Phase 2Unknown
- Sponsor
- University Hospital Southampton
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and varlilumab in malignant B-cell neoplasm and B-cell malignancy, sponsored by University Hospital Southampton. Primary endpoint: Safety (adverse events causality and severity). Status: unknown.
02
Drugs
rituximabvarlilumab
03
Conditions
malignant B-cell neoplasmB-cell malignancy
Beyond the preview
Go deeper on 2017-000302-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000302-37.